April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Down-Regulation of VEGF by RTEF-1 in Ocular Melanoma Cells
Author Affiliations & Notes
  • T. J. McFarland
    Casey Eye Institute-OHSU, Portland, Oregon
  • A. L. Dye
    Casey Eye Institute-OHSU, Portland, Oregon
  • B. Ksander
    Harvard Medical School, Schepens Eye Research Inst., Boston, Massachusetts
  • J. Smith
    Casey Eye Institute-OHSU, Portland, Oregon
  • J. T. Stout
    Casey Eye Institute-OHSU, Portland, Oregon
  • B. Appukuttan
    Casey Eye Institute-OHSU, Portland, Oregon
  • Footnotes
    Commercial Relationships  T.J. McFarland, None; A.L. Dye, None; B. Ksander, None; J. Smith, None; J.T. Stout, None; B. Appukuttan, None.
  • Footnotes
    Support  Clayton Foundation for Research, Collins Medical Trust, Research to Prevent Blindness, NIH:NEI:RO1 EY019042
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 1685. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. J. McFarland, A. L. Dye, B. Ksander, J. Smith, J. T. Stout, B. Appukuttan; Down-Regulation of VEGF by RTEF-1 in Ocular Melanoma Cells. Invest. Ophthalmol. Vis. Sci. 2010;51(13):1685.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Uveal melanoma is the leading ocular cancer observed in U.S. adults today. Treatment options for ocular melanoma vary depending on the tumor size and location within the globe. Often enucleation is the treatment for large tumors. We have previously demonstrated that the 651 isoform of the related transcription enhancer factor-1 (RTEF-1) gene is effective at modulating VEGF gene expression. Due to the importance VEGF plays in tumor growth, it is an ideal target for therapy. The purpose of this study is to evaluate the effect of the 651 RTEF-1 isoform on ocular melanoma cells in culture.

Methods: : Mel 202 cells were grown in culture until 80% confluent. An equal number of naive cells were plated or transfected with CMV-RTEF-1 651 or GFP plasmid using the Amaxa electroporation device with an optimized protocol. After 24 hours, the media was changed and cells were exposed to a 1% oxygen environment for 4 hours to mimic hypoxia. Media was collected for VEGF ELISA, which was normalized to total media protein, and RNA was isolated for VEGF and RTEF-1 analysis by RT-PCR.

Results: : By light microscopy there were more cells with a rounded abnormal morphology in the 651 transfected group compared to the GFP group. There was a 50% reduction in VEGF protein in the 651treated group compared to naive cells (n = 3, p=0.01). Semi-quantitative RT-PCR revealed the presence of the 651 transgene in the transfected samples and a decrease in VEGF levels compared to the control.

Conclusions: : As evidenced by these data, RTEF-1 651 was capable of down-regulating VEGF and appears to impact cellular properties of this ocular melanoma cell line. Studies currently underway involve cellular proliferation and determining whether an apoptotic pathway is involved in the morphologic properties observed.

Keywords: melanoma • vascular endothelial growth factor • transcription factors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.